Nektar Corp (NKTR) - Long-Term Debt to Capital Coefficient
Nektar Therapeutics (NKTR) generates revenue through the sale of proprietary drug delivery systems, grants, and licensing royalties for developments in oncology and immunology. The business maintains geopolitical stability due to the humanitarian status of its research and its localization within Western jurisdictions. The company is currently optimizing expenses and developing a promising dermatitis drug in collaboration with Eli Lilly, which is recorded at 0.14. The asset's price trajectory is illustrated in the chart below.
%20Long-Term%20Debt%20to%20Capital&width=1200&height=400&colorIndex=0&v=mvx9zauv.4e-7b561vk&start=20220704&end=20261031&filename=GURU_Markets_-_NKTR_-_Nektar-Therapeutics_-_Long-Term-Debt-to-Capital "NKTR: Nektar Therapeutics Inc. Long-Term Debt to Capital 07/04/2022 - 10/31/2026 | 👁️GURU.Markets👁️")
Comprehensive metric breakdowns and analytics for Nektar Therapeutics (NKTR)
- stock price and consensus target price:
- market capitalization indicators:
- balance sheet net asset value indicators:
- debt and solvency information:
Total Debt to Equity Ratio Nektar Therapeutics|NKTR - Long-Term Debt to Capital|Short-Term Debt to Capital nektar.com|NKTR - Company Total Debt|Debt to Net Assets Ratio Nektar Therapeutics Inc.|NKTR - Company Long-Term Debts|Short-Term Debt Volume Nektar Therapeutics|Quick Liquidity Indicator nektar.com
- net income and valuation ratios data:
General company analysis:Nektar Therapeutics Inc - NKTR
This ratio compares liabilities with a maturity of over one year to equity value, determining the business's degree of dependence on external debt financing. Amid geopolitical risks for Nektar Therapeutics (NKTR) and the complexity of clinical trials, the long-term debt-to-equity trend confirms the company's ability to maintain operational autonomy without a critical debt burden.
Key competitors
argenx N.V. - Long-Term Liabilities to Equity|Long-Term Debt to Capital BNTX|ABVX (Abivax S.A.) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital ADMA (ADMA Biologics)|Long-Term Debt to Capital protagonist-inc.com PTGX|IMVT - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient KNSA (Kiniksa Pharmaceuticals, Ltd.)|Grifols Group (GRFS) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Adaptive Biotechnologies Inc.|CLDX (Celldex Therapeutics) - Long-Term Debt to Capital|Long-Term Debt to Capital auriniapharma.com|Long-Term Debt to Equity Ratio BCRX (BioCryst Pharmaceuticals)|VERA (Vera Therapeutics Inc) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital DNTH (Dianthus Pharma)|Ratio of Long-Term Indebtedness to Capital Pharvaris Pharma (PHVS)|ABCL - Long-Term Debt to Equity|tourmalinebio.com (TRML) - Long-Term Debt to Equity Ratio|Precigen (PGEN) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Pharming Group NV|Long-Term Debt to Equity Ratio UPB|Long-Term Debt to Capital Zenas Corp|Long-Term Debt to Equity Immunome, Inc. (IMNM)|gossamerbio.com - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital KALV (KalVista Pharmaceuticals, Inc.)|Septerna, Inc. (SEPN) - Long-Term Liabilities to Capital|PVLA - Long-Term Debt to Equity|SVRA (Savara Pharma) - Long-Term Debt to Capital Ratio|RIGL: Long-Term Debt to Capital|Long-Term Liabilities to Capital anaptysbio.com (ANAB)|Long-Term Debt to Equity Astria Therapeutics, Inc.|Long-Term Debt to Capital enGene Holdings Inc|Long-Term Debt to Equity Ratio RAPT (RAPT Therapeutics, Inc.)|Long-Term Loans to Capital Ratio JBIO|Long-Term Debt to Capital ACRS (Aclaris Therapeutics)|Long-Term Debt to Capital kyvernatx.com KYTX|TLSA - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient CABA (Cabaletta Bio Inc.)|VTYX (Ventyx Bio) - Long-Term Debt to Equity Ratio|Theratechnologies, Inc - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Ratio AVTX|ELDN (eledon.com) - Long-Term Loans to Capital Ratio|Long-Term Debt to Capital AGEN|CLYM (Climb Bio Inc.) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital ZURA (Zura Bio Limited)|aTyr Pharmaceuticals (ATYR) - Long-Term Liabilities to Capital|ADAG - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient IMA (ImageneBio Inc)|STTK: Long-Term Debt to Capital|Equillium (EQ) - Long-Term Debt to Capital|Long-Term Debt to Equity Connect Biopharma Holdings|Immunic Inc - Long-Term Liabilities to Equity|Long-Term Debt to Capital ATRA|IFRX - Long-Term Liabilities to Capital|X4 Pharmaceuticals, Inc. - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Adicet Bio Inc. ACET|CELU: Long-Term Debt to Equity Ratio|INmune Bio Corporation - Long-Term Loans to Capital Ratio|BRNS: Long-Term Debt to Capital|KZR - Ratio of Long-Term Indebtedness to Capital|SABS (SAB Biotherapeutics, Inc.) - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio Akari Therapeutics PLC (AKTX)|Long-Term Debt to Equity Enlivex Therapeutics (ENLV)|Ratio of Long-Term Indebtedness to Capital q32bio.com|Long-Term Debt to Equity GeoVax Labs, Inc. GOVX|EDSA: Long-Term Debt to Capital Ratio|IBIO - Long-Term Debt to Equity|CARM - Long-Term Debt to Capital|XTLB (XTL Biopharmaceuticals, Ltd.) - Long-Term Debt to Equity Ratio|BOLT: Long-Term Loans to Capital Ratio|Long-Term Debt to Equity HCW Biologics, Inc.|APVO: Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity AIM ImmunoTech (AIM)|ADTX: Long-Term Liabilities to Equity|Long-Term Debt to Capital GRI (GRI Bio Corp)|Long-Term Debt to Capital Coefficient XRTX|Vyome Holdings Inc - Long-Term Debt to Capital|REVB - Long-Term Debt to Capital|Indaptus Therapeutics, Inc. (INDP) - Long-Term Debt to Equity|Scinai Immunotherapeutics Ltd - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity CalciMedica Inc|Long-Term Debt to Equity Ratio Affimed Therapeutics (AFMD)|Long-Term Debt to Capital ALLK|Long-Term Debt to Capital hookipapharma.com (HOOK)|IGM Biosciences - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient ITOS|Ocean Bio - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital TC BioPharm Ltd TCBP|Third Harmonic Bio (THRD) - Long-Term Debt to Equity